{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:17:35Z","timestamp":1794565055409,"version":"4.9.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Urovant Sciences","id":[{"id":"https:\/\/ror.org\/02sdbec13","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40266-023-01056-y","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T10:48:45Z","timestamp":1694688525000},"page":"895-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Crushed Tablet Administration for Patients with Dysphagia and Enteral Feeding: Challenges and Considerations"],"prefix":"10.1007","volume":"40","author":[{"given":"Amie","family":"Blaszczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Tuders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Doles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Stefanacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"1056_CR1","doi-asserted-by":"publisher","first-page":"21955","DOI":"10.1038\/s41598-021-99858-w","volume":"11","author":"U Wolf","year":"2021","unstructured":"Wolf U, Eckert S, Walter G, et al. Prevalence of oropharyngeal dysphagia in geriatric patients and real-life associations with diseases and drugs. Sci Rep. 2021;11:21955.","journal-title":"Sci Rep"},{"key":"1056_CR2","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1177\/000348940711601112","volume":"116","author":"N Roy","year":"2007","unstructured":"Roy N, Stemple J, Merrill RM, et al. Dysphagia in the elderly: preliminary evidence of prevalence, risk factors, and socioemotional effects. Ann Otol Rhinol Laryngol. 2007;116:858\u201365.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"1056_CR3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/j.1442-2050.2011.01182.x","volume":"24","author":"G Holland","year":"2011","unstructured":"Holland G, Jayasekeran V, Pendleton N, et al. Prevalence and symptom profiling of oropharyngeal dysphagia in a community dwelling of an elderly population: a self-reporting questionnaire survey. Dis Esophagus. 2011;24:476\u201380.","journal-title":"Dis Esophagus"},{"key":"1056_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ncp.10239","volume":"34","author":"CM McGinnis","year":"2019","unstructured":"McGinnis CM, Homan K, Solomon M, et al. Dysphagia: interprofessional management, impact, and patient-centered care. Nutr Clin Pract. 2019;34:80\u201395.","journal-title":"Nutr Clin Pract"},{"key":"1056_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00455-008-9170-3","volume":"24","author":"J Kelly","year":"2009","unstructured":"Kelly J, D\u2019Cruz G, Wright D. A qualitative study of the problems surrounding medicine administration to patients with dysphagia. Dysphagia. 2009;24:49\u201356.","journal-title":"Dysphagia"},{"key":"1056_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12877-019-1337-2","volume":"19","author":"E Belissa","year":"2019","unstructured":"Belissa E, Vallet T, Laribe-Caget S, et al. Acceptability of oral liquid pharmaceutical products in older adults: palatability and swallowability issues. BMC Geriatr. 2019;19:344.","journal-title":"BMC Geriatr"},{"key":"1056_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/ijn.12446","volume":"22","author":"H Clauson","year":"2016","unstructured":"Clauson H, Rull F, Thibault M, et al. Crushing oral solid drugs: assessment of nursing practices in health-care facilities in Auvergne, France. Int J Nurs Pract. 2016;22:384\u201390.","journal-title":"Int J Nurs Pract"},{"key":"1056_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/0148607108330314","volume":"33","author":"R Bankhead","year":"2009","unstructured":"Bankhead R, Boullata J, Brantley S, et al. Enteral nutrition practice recommendations. J Parenter Enteral Nutr. 2009;33:122\u201367.","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"1056_CR9","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/pme.12834","volume":"16","author":"J Gudin","year":"2015","unstructured":"Gudin J, Levy-Cooperman N, Kopecky EA, et al. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015;16:2142\u201351.","journal-title":"Pain Med"},{"key":"1056_CR10","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.2146\/ajhp080155","volume":"65","author":"NT Williams","year":"2008","unstructured":"Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008;65:2347\u201357.","journal-title":"Am J Health Syst Pharm"},{"key":"1056_CR11","volume-title":"Handbook of drug administration via enteral feeding tubes","author":"R White","year":"2015","unstructured":"White R, Bradnam V. Handbook of drug administration via enteral feeding tubes. 3rd ed. London: Pharmaceutical Press; 2015.","edition":"3"},{"key":"1056_CR12","volume-title":"Appendix PP\u2014guidance to surveyors for long term care facilities","author":"Centers for Medicare & Medicaid Services","year":"2022","unstructured":"Centers for Medicare & Medicaid Services. Appendix PP\u2014guidance to surveyors for long term care facilities. Baltimore: Centers for Medicare & Medicaid Services; 2022."},{"key":"1056_CR13","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1111\/jocn.15498","volume":"29","author":"H Tillott","year":"2020","unstructured":"Tillott H, Barrett D, Ruan J, et al. Survey of nurses\u2019 knowledge and practice regarding medication administration using enteral tubes. J Clin Nurs. 2020;29:4614\u201322.","journal-title":"J Clin Nurs"},{"key":"1056_CR14","first-page":"287","volume":"7","author":"L Sura","year":"2012","unstructured":"Sura L, Madhavan A, Carnaby G, et al. Dysphagia in the elderly: management and nutritional considerations. Clin Interv Aging. 2012;7:287\u201398.","journal-title":"Clin Interv Aging"},{"key":"1056_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/MCG.0000000000000307","volume":"49","author":"JR Malagelada","year":"2015","unstructured":"Malagelada JR, Bazzoli F, Boeckxstaens G, et al. World Gastroenterology Organisation global guidelines: dysphagia\u2013global guidelines and cascades update September 2014. J Clin Gastroenterol. 2015;49:370\u20138.","journal-title":"J Clin Gastroenterol"},{"key":"1056_CR16","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1161\/01.STR.0000190056.76543.eb","volume":"36","author":"R Martino","year":"2005","unstructured":"Martino R, Foley N, Bhogal S, et al. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke. 2005;36:2756\u201363.","journal-title":"Stroke"},{"key":"1056_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.parkreldis.2011.11.006","volume":"18","author":"JG Kalf","year":"2012","unstructured":"Kalf JG, de Swart BJ, Bloem BR, et al. Prevalence of oropharyngeal dysphagia in Parkinson\u2019s disease: a meta-analysis. Parkinsonism Relat Disord. 2012;18:311\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"1056_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.archger.2012.04.011","volume":"56","author":"K Alagiakrishnan","year":"2013","unstructured":"Alagiakrishnan K, Bhanji RA, Kurian M. Evaluation and management of oropharyngeal dysphagia in different types of dementia: a systematic review. Arch Gerontol Geriatr. 2013;56:1\u20139.","journal-title":"Arch Gerontol Geriatr"},{"key":"1056_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.7224\/1537-2073-2.1.40","volume":"2","author":"K Balzer","year":"2000","unstructured":"Balzer K. Drug-induced dysphagia. Int J MS Care. 2000;2:40\u201350.","journal-title":"Int J MS Care."},{"key":"1056_CR20","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1097\/MEG.0000000000000983","volume":"29","author":"M Miarons Font","year":"2017","unstructured":"Miarons Font M, Rofes Salsench L. Antipsychotic medication and oropharyngeal dysphagia: systematic review. Eur J Gastroenterol Hepatol. 2017;29:1332\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1056_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/flgastro-2013-100316","volume":"5","author":"HL Philpott","year":"2014","unstructured":"Philpott HL, Nandurkar S, Lubel J, et al. Drug-induced gastrointestinal disorders. Frontline Gastroenterol. 2014;5:49\u201357.","journal-title":"Frontline Gastroenterol."},{"key":"1056_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jstrokecerebrovasdis.2011.01.004","volume":"21","author":"GW Ickenstein","year":"2012","unstructured":"Ickenstein GW, H\u00f6hlig C, Prosiegel M, et al. Prediction of outcome in neurogenic oropharyngeal dysphagia within 72 hours of acute stroke. J Stroke Cerebrovasc Dis. 2012;21:569\u201376.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1056_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00455-016-9758-y","volume":"32","author":"JA Cichero","year":"2017","unstructured":"Cichero JA, Lam P, Steele CM, et al. Development of international terminology and definitions for texture-modified foods and thickened fluids used in dysphagia management: the IDDSI Framework. Dysphagia. 2017;32:293\u2013314.","journal-title":"Dysphagia"},{"key":"1056_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/jtxs.12481","volume":"51","author":"JAY Cichero","year":"2020","unstructured":"Cichero JAY, Lam PTL, Chen J, et al. Release of updated international dysphagia diet standardisation initiative framework (IDDSI 2.0). J Texture Stud. 2020;51:195\u20136.","journal-title":"J Texture Stud"},{"key":"1056_CR25","unstructured":"International Dysphagia Diet Standardisation Initiative. https:\/\/iddsi.org\/. Accessed 12 Apr 2023."},{"key":"1056_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3988\/jcn.2018.14.3.265","volume":"14","author":"IE Virvidaki","year":"2018","unstructured":"Virvidaki IE, Nasios G, Kosmidou M, et al. Swallowing and aspiration risk: a critical review of non instrumental bedside screening tests. J Clin Neurol. 2018;14:265\u201374.","journal-title":"J Clin Neurol"},{"key":"1056_CR27","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1111\/j.1365-2648.2011.05700.x","volume":"67","author":"J Kelly","year":"2011","unstructured":"Kelly J, Wright D, Wood J. Medicine administration errors in patients with dysphagia in secondary care: a multi-centre observational study. J Adv Nurs. 2011;67:2615\u201327.","journal-title":"J Adv Nurs"},{"key":"1056_CR28","doi-asserted-by":"crossref","unstructured":"Wright DJ, Smithard DG, Griffith R. Optimising medicines administration for patients with dysphagia in hospital: medical or nursing responsibility? Geriatrics (Basel). 2020;5:9.","DOI":"10.3390\/geriatrics5010009"},{"key":"1056_CR29","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1503\/cmaj.050176","volume":"172","author":"P Cornish","year":"2005","unstructured":"Cornish P. \u201cAvoid the crush\u201d: hazards of medication administration in patients with dysphagia or a feeding tube. Can Med Assoc J. 2005;172:871\u20132.","journal-title":"Can Med Assoc J"},{"key":"1056_CR30","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1345\/aph.1D091","volume":"37","author":"JG Schier","year":"2003","unstructured":"Schier JG, Howland MA, Hoffman RS, et al. Fatality from administration of labetalol and crushed extended-release nifedipine. Ann Pharmacother. 2003;37:1420\u20133.","journal-title":"Ann Pharmacother"},{"key":"1056_CR31","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/0115426503018005402","volume":"18","author":"RN Dickerson","year":"2003","unstructured":"Dickerson RN, Tidwell AC, Brown RO. Adverse effects from inappropriate medication administration via a jejunostomy feeding tube. Nutr Clin Pract. 2003;18:402\u20135.","journal-title":"Nutr Clin Pract"},{"issue":"3","key":"1056_CR32","first-page":"14850","volume":"17","author":"JF Mitchell","year":"1982","unstructured":"Mitchell JF, Liadis M. Oral solid dosage forms that should not be crushed prior to administration. Hosp Pharm. 1982;17:14850,155\u20136.","journal-title":"Hosp Pharm"},{"key":"1056_CR33","unstructured":"Institute for Safe Medication Practices. Oral dosage forms that should not be crushed. https:\/\/www.ismp.org\/recommendations\/do-not-crush. Accessed 15 Sept 2022."},{"key":"1056_CR34","unstructured":"The NEWT guidelines for administration of medication to patients with enteral feeding tubes or swallowing difficulties. https:\/\/www.newtguidelines.com\/. Accessed 28 Apr 2023."},{"key":"1056_CR35","unstructured":"Swallowing Difficulties. https:\/\/www.swallowingdifficulties.com\/. Accessed 17 Apr 2023."},{"key":"1056_CR36","unstructured":"U.S. Pharmacopeia. USP General Chapter <800> Hazardous drugs\u2014handling in healthcare settings. https:\/\/www.usp.org\/compounding\/general-chapter-hazardous-drugs-handling-healthcare. U.S. Pharmacopeia; 2020."},{"key":"1056_CR37","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s12603-017-0886-3","volume":"21","author":"M Fodil","year":"2017","unstructured":"Fodil M, Nghiem D, Colas M, et al. Assessment of clinical practices for crushing medication in geriatric units. J Nutr Health Aging. 2017;21:904\u20138.","journal-title":"J Nutr Health Aging"},{"key":"1056_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193683","volume":"13","author":"MY Thong","year":"2018","unstructured":"Thong MY, Manrique YJ, Steadman KJ. Drug loss while crushing tablets: comparison of 24 tablet crushing devices. PLoS ONE. 2018;13:e0193683.","journal-title":"PLoS ONE"},{"key":"1056_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.18433\/J39W3V","volume":"17","author":"YJ Manrique","year":"2014","unstructured":"Manrique YJ, Lee DJ, Islam F, et al. Crushed tablets: does the administration of food vehicles and thickened fluids to aid medication swallowing alter drug release? J Pharm Pharm Sci. 2014;17:207\u201319.","journal-title":"J Pharm Pharm Sci"},{"key":"1056_CR40","volume-title":"Clarification of guidance related to medication errors and pharmacy services, Ref S&C: 13\u201302-NH","author":"Centers for Medicare & Medicaid Services","year":"2012","unstructured":"Centers for Medicare & Medicaid Services. Clarification of guidance related to medication errors and pharmacy services, Ref S&C: 13\u201302-NH. Baltimore: Centers for Medicare & Medicaid Services; 2012."},{"key":"1056_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/j.2055-2335.2009.tb00436.x","volume":"39","author":"LM Nissen","year":"2009","unstructured":"Nissen LM, Haywood A, Steadman KJ. Solid medication dosage form modification at the bedside and in the pharmacy of Queensland hospitals. J Pharm Pract Res. 2009;39:129\u201334.","journal-title":"J Pharm Pract Res"},{"key":"1056_CR42","unstructured":"US Food and Drug Administration. Tablet scoring: nomenclature, labeling and data for evaluation. FDA.gov: FDA; 2013."},{"key":"1056_CR43","first-page":"5733","volume":"7","author":"J Sun","year":"2012","unstructured":"Sun J, Wang F, Sui Y, et al. Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q10 as naked nanocrystals. Int J Nanomed. 2012;7:5733\u201344.","journal-title":"Int J Nanomed"},{"key":"1056_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120151","volume":"594","author":"M Swedrowska","year":"2021","unstructured":"Swedrowska M, Ingham S, Tomlin S, et al. Recommendations for crushing Circadin\u00ae (melatonin) tablets for safe and reliable delivery via pediatric nasogastric tubes. Int J Pharm. 2021;594: 120151.","journal-title":"Int J Pharm"},{"key":"1056_CR45","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jpainsymman.2020.09.020","volume":"61","author":"AG Lovell","year":"2021","unstructured":"Lovell AG, Protus BM, Dickman JR, et al. Palatability of crushed over-the-counter medications. J Pain Symptom Manag. 2021;61:755\u201362.","journal-title":"J Pain Symptom Manag"},{"key":"1056_CR46","unstructured":"US Food and Drug Administration. Use of liquids and\/or soft foods as vehicles for drug administration: general considerations for selection and in vitro methods for product quality assessments. Guidance for industry. Silver Spring; 2018."},{"issue":"7","key":"1056_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.05.004","volume":"38","author":"Y Song","year":"2016","unstructured":"Song Y, Chang M, Suzuki A, et al. Evaluation of crushed tablet for oral administration and the effect of food on apixaban pharmacokinetics in healthy adults. Clin Ther. 2016;38:1674\u201385.e1.","journal-title":"Clin Ther"},{"key":"1056_CR48","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/cpdd.1169","volume":"11","author":"J King","year":"2022","unstructured":"King J, Walker A, Aikin D, et al. Pharmacokinetics and safety of vibegron 75 mg administered as an intact or crushed tablet in healthy adults. Clin Pharmacol Drug Dev. 2022;11:1349\u201355.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1056_CR49","unstructured":"Urovant Sciences. Gemtesa (vibegron) tablets new drug application. Application number: 213-006; 2020."},{"key":"1056_CR50","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5414\/CP202202","volume":"53","author":"R Teng","year":"2015","unstructured":"Teng R, Carlson G, Hsia J. An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. Int J Clin Pharmacol Ther. 2015;53:182\u20139.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1056_CR51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/jps.23359","volume":"102","author":"LZ Benet","year":"2013","unstructured":"Benet LZ. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci. 2013;102:34\u201342.","journal-title":"J Pharm Sci"},{"key":"1056_CR52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejps.2014.01.009","volume":"57","author":"Y Tsume","year":"2014","unstructured":"Tsume Y, Mudie DM, Langguth P, et al. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci. 2014;57:152\u201363.","journal-title":"Eur J Pharm Sci"},{"key":"1056_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1208\/s12248-020-0417-8","volume":"22","author":"DM Mudie","year":"2020","unstructured":"Mudie DM, Samiei N, Marshall DJ, et al. Selection of in vivo predictive dissolution media using drug substance and physiological properties. AAPS J. 2020;22:34.","journal-title":"AAPS J"},{"key":"1056_CR54","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/ajhp\/61.11.1135","volume":"61","author":"MN Carrier","year":"2004","unstructured":"Carrier MN, Garinot O, Vitzling C. Stability and compatibility of tegaserod from crushed tablets mixed in beverages and foods. Am J Health Syst Pharm. 2004;61:1135\u201342.","journal-title":"Am J Health Syst Pharm"},{"key":"1056_CR55","unstructured":"Optimer Pharmaceuticals. DIFICID (fidamoxicin) tablets new drug application. Application number: 201-699; 2010."},{"key":"1056_CR56","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40268-014-0067-3","volume":"14","author":"A Tousseeva","year":"2014","unstructured":"Tousseeva A, Jackson JD, Redell M, et al. Stability and recovery of DIFICID\u00ae (fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tube. Drugs R D. 2014;14:309\u201314.","journal-title":"Drugs R D."},{"key":"1056_CR57","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1111\/ggi.13104","volume":"17","author":"S Mabuchi","year":"2017","unstructured":"Mabuchi S, Ouchi S, Suzuki R, et al. Case report of an undisintegrated magnesium oxide tablet in the stool in an elderly patient taking food thickener. Geriatr Gerontol Int. 2017;17:2615\u20136.","journal-title":"Geriatr Gerontol Int"},{"key":"1056_CR58","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00455-017-9787-1","volume":"32","author":"T Tomita","year":"2017","unstructured":"Tomita T, Goto H, Sumiya K, et al. Effect of food thickener on the inhibitory effect of mitiglinide tablets on post-prandial elevation of blood glucose levels. Dysphagia. 2017;32:449\u201353.","journal-title":"Dysphagia"},{"key":"1056_CR59","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2334\/josnusd.19-0370","volume":"62","author":"E Matsumura","year":"2020","unstructured":"Matsumura E, Nohara K, Tanaka N, et al. A survey on medications received by elderly persons with dysphagia living at home or in a nursing home. J Oral Sci. 2020;62:239\u201341.","journal-title":"J Oral Sci"},{"key":"1056_CR60","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jamda.2008.10.010","volume":"10","author":"S Kuo","year":"2009","unstructured":"Kuo S, Rhodes RL, Mitchell SL, et al. Natural history of feeding-tube use in nursing home residents with advanced dementia. J Am Med Dir Assoc. 2009;10:264\u201370.","journal-title":"J Am Med Dir Assoc"},{"key":"1056_CR61","unstructured":"Society of Hospital Pharmacists of Australia. Don't Rush to Crush. 4th ed. Collingwood, VIC, Australia: Society of Hospital Pharmacists of Australia; 2022."},{"key":"1056_CR62","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.medmal.2019.10.010","volume":"50","author":"C San","year":"2020","unstructured":"San C, Le MP, Matheron S, et al. Management of oral antiretroviral administration in patients with swallowing disorders or with an enteral feeding tube. Med Mal Infect. 2020;50:537\u201344.","journal-title":"Med Mal Infect"},{"key":"1056_CR63","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0885-3924(98)00124-9","volume":"17","author":"PJ Gilbar","year":"1999","unstructured":"Gilbar PJ. A guide to enteral drug administration in palliative care. J Pain Symptom Manag. 1999;17:197\u2013207.","journal-title":"J Pain Symptom Manag"},{"key":"1056_CR64","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/01.NAJ.0000361488.45094.28","volume":"109","author":"JI Boullata","year":"2009","unstructured":"Boullata JI. Drug administration through an enteral feeding tube. Am J Nurs. 2009;109:34\u201342.","journal-title":"Am J Nurs"},{"key":"1056_CR65","volume-title":"Xarelto (rivaroxaban). Full prescribing information","author":"Janssen Pharmaceuticals","year":"2021","unstructured":"Janssen Pharmaceuticals. Xarelto (rivaroxaban). Full prescribing information. Titusville: Janssen Pharmaceuticals; 2021."},{"key":"1056_CR66","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/nmo.12467","volume":"27","author":"SY Cho","year":"2015","unstructured":"Cho SY, Choung RS, Saito YA, et al. Prevalence and risk factors for dysphagia: a USA community study. Neurogastroenterol Motil. 2015;27:212\u20139.","journal-title":"Neurogastroenterol Motil"},{"key":"1056_CR67","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00228-012-1417-0","volume":"69","author":"JT Schiele","year":"2013","unstructured":"Schiele JT, Quinzler R, Klimm HD, et al. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2013;69:937\u201348.","journal-title":"Eur J Clin Pharmacol"},{"key":"1056_CR68","doi-asserted-by":"crossref","unstructured":"Godaert L, Cofais C, Proye E, et al. Medication modification in a population of community-dwelling individuals aged 65 years or older. Age Ageing. 2022;51:afab240.","DOI":"10.1093\/ageing\/afab240"},{"key":"1056_CR69","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1177\/000348940811701210","volume":"117","author":"PC Belafsky","year":"2008","unstructured":"Belafsky PC, Mouadeb DA, Rees CJ, et al. Validity and reliability of the Eating Assessment Tool (EAT-10). Ann Otol Rhinol Laryngol. 2008;117:919\u201324.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"1056_CR70","unstructured":"Eating Assessment Tool (EAT-10) English. https:\/\/www.nestlenutrition-institute.org\/resources\/nutrition-tools\/details\/swallowing-assessment-tool. Accessed 22 May 2023."},{"key":"1056_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211040","volume":"14","author":"K Igarashi","year":"2019","unstructured":"Igarashi K, Kikutani T, Tamura F. Survey of suspected dysphagia prevalence in home-dwelling older people using the 10-Item Eating Assessment Tool (EAT-10). PLoS ONE. 2019;14: e0211040.","journal-title":"PLoS ONE"},{"key":"1056_CR72","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12955-020-01384-2","volume":"18","author":"T Hansen","year":"2020","unstructured":"Hansen T, Kjaersgaard A. Item analysis of the Eating Assessment Tool (EAT-10) by the Rasch model: a secondary analysis of cross-sectional survey data obtained among community-dwelling elders. Health Qual Life Outcomes. 2020;18:139.","journal-title":"Health Qual Life Outcomes"},{"key":"1056_CR73","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s40520-020-01707-9","volume":"33","author":"S Castejon-Hernandez","year":"2021","unstructured":"Castejon-Hernandez S, Latorre-Vallbona N, Molist-Brunet N, et al. Association between anticholinergic burden and oropharyngeal dysphagia among hospitalized older adults. Aging Clin Exp Res. 2021;33:1981\u20135.","journal-title":"Aging Clin Exp Res"},{"key":"1056_CR74","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.gie.2010.10.043","volume":"73","author":"R Sharma","year":"2011","unstructured":"Sharma R, DeCross AJ. Zenker\u2019s diverticulitis secondary to alendronate ingestion: a rare cause of recurrent dysphagia. Gastrointest Endosc. 2011;73:368\u201370.","journal-title":"Gastrointest Endosc"},{"key":"1056_CR75","volume-title":"Norvasc (amlodipine besylate). Full prescribing information","author":"Pfizer","year":"2011","unstructured":"Pfizer. Norvasc (amlodipine besylate). Full prescribing information. New York: Pfizer; 2011."},{"key":"1056_CR76","doi-asserted-by":"crossref","unstructured":"Lee JC, Takeshita J. Antipsychotic-induced dysphagia: a case report. Prim Care Companion CNS Disord. 2015;17.","DOI":"10.4088\/PCC.15l01792"},{"key":"1056_CR77","doi-asserted-by":"publisher","first-page":"56","DOI":"10.9740\/mhc.2017.03.056","volume":"7","author":"EL Crouse","year":"2017","unstructured":"Crouse EL, Alastanos JN, Bozymski KM, et al. Dysphagia with second-generation antipsychotics: a case report and review of the literature. Ment Health Clin. 2017;7:56\u201364.","journal-title":"Ment Health Clin."},{"key":"1056_CR78","doi-asserted-by":"publisher","first-page":"220","DOI":"10.5056\/jnm.2012.18.2.220","volume":"18","author":"KW Jung","year":"2012","unstructured":"Jung KW, Myung SJ, Jung HY. A patient with dysphagia associated with opioid medication. J Neurogastroenterol Motil. 2012;18:220\u20131.","journal-title":"J Neurogastroenterol Motil."}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01056-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-023-01056-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01056-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T09:26:58Z","timestamp":1695202018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-023-01056-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":78,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1007\/s40266-023-01056-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"19 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for medical writing and editorial support in the preparation of this manuscript was provided by Sumitomo Pharma America, Inc. (formerly\u00a0Urovant Sciences, Inc.; Marlborough, MA, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AB has consulted for AstraZeneca and serves as a geriatrics content consultant for Wolters Kluwer. NT and HD have nothing to disclose. NB is a consultant for Institute for Healthcare Improvement (Faculty), is section editor for SLACK, Inc., and is an author of the American Geriatrics Society Beers Criteria<sup>\u00ae<\/sup> for Potentially Inappropriate Medication Use in Older Adults. JA is a consultant pharmacist with Medication Managers and a Clinical Pharmacist, Pharmacy Corporate Development, with Brookshire Grocery Company. RGS is an advisor for Sumitomo Pharma America.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent for publication, Code availability"}},{"value":"The first draft of this manuscript was written by a medical writer under the direction of the authors. All authors participated in the review and interpretation of literature and relevant data, critically revised the work for intellectual content, and read and approved the final version for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}